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Haploidentical hematopoietic stem cell transplantation (HSCT) offers the beneﬁts of rapid and nearly
universal donor availability and has been accepted worldwide as an alternative treatment for patients
with hematologic malignancies who do not have a completely HLA-matched sibling or who require urgent
transplantation. Unfortunately, serious infections and leukemia relapse resulting from slow immune
reconstitution remain the 2 most frequent causes of mortality in patients undergoing haploidentical HSCT,
particularly in those receiving extensively T celledepleted megadose CD34þ allografts. This review
summarizes advances in immune recovery after haploidentical HSCT, focusing on the immune subsets
likely to have the greatest impact on clinical outcomes. The progress made in accelerating immune
reconstitution using different strategies after haploidentical HSCT is also discussed. It is our belief that a
predictive immune subseteguided strategy to improve immune recovery might represent a future clinical
direction.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Haploidentical hematopoietic stem cell (HSC) trans-
plantation (HSCT) is available for nearly all patients and has
no search or acquisition costs [1-9]. Over the past decade,
many haploidentical transplantation protocols, including T
cellereplete and T celledepleted (TCD) haplotype HSCT,
depending on whether or not allografts have been engi-
neered in vitro, have demonstrated promising clinical out-
comes [4,8,9]. Unfortunately, serious infections and disease
relapse resulting from delayed immune reconstitution
remain the 2 most frequent causes of mortality after allo-
geneic HSCT, particularly in patients who received exten-
sively TCD CD34þ cell megadose allografts [10-15]. Advances
in the understanding of immune recovery proﬁles in hap-
loidentical recipients [8,16-47], along with new methods of
modifying donor T cells [48-50] and natural killer (NK) cells
[51], have made it possible to establish new strategies to
improve post-transplantation immunologic reconstitution
[9,52-58].
In this review, we summarize advances in immune
recovery after haploidentical HSCT, focusing on the recov-
ered immune subsets likely to have the greatest impact
on clinical outcomes [18,23,33,42,45,59-63]. We compare
the differences in immune reconstitution between hap-
loidentical transplantation and other transplantation stra-
tegies, including HLA-identical sibling donor transplantation,
HLA-matched unrelated donor transplantation, and umbili-
cal cord blood transplantation. In addition, we discuss recent
advances in the enhancement of immune reconstitution af-
ter haploidentical HSCT [64-70].edgments on page 447.
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13.11.028KINETICS OF IMMUNE RECOVERY AFTER
HAPLOIDENTICAL HSCT
Different immune cell subgroups recover at different rates
after haploidentical HSCT (Table 1). The conditioning regimen
is followed by a “neutropenic” phase that lasts until neutro-
phils reconstitute, at a median of approximately 11 to 12 days
after TCD HSCT with high doses of CD34þ cells [8,38],
approximately 15 days after unmanipulated haploidentical
steady-state bone marrow (BM) allografts, approximately
21 days after granulocyte colony-stimulating factor (G-CSF)-
primed BM allografts, and approximately 13 days after
G-CSFestimulated blood and BM allografts [2,7,71]. The re-
covery of neutrophil function (eg, chemotaxis, phagocytosis,
superoxide production, killing of bacteria) in haploidentical
settings remains poorly understood, however.
The rapid recovery of NK cells after haploidentical trans-
plantation is based on an expansion of the cytokine-
producing CD56bright NK cell subsets in both T cellereplete
and TCD settings [16,17,24,41]. Although the absolute num-
ber of overall NK cells usually recovers to the donor’s level by
day 30 post-HSCT, recovery may be delayed by the devel-
opment of graft-versus-host disease (GVHD) [8,24]. The
function of NK cell recovery is regulated by the balance of
activating and inhibitory signals transmitted by different cell
surface receptors. Thus, the expression of activating NK re-
ceptors (NKRs), such as NKP46, NKP44, NKP30, and NKG2D,
as well as inhibiting NKRs, such as CD158a, CD158b, CD158e,
and NKG2A, is essential for NK cell activation.
After haploidentical HSCT, the overall expression of acti-
vating NKRs and inhibitory NKRs is reduced, whereas CD94/
NKG2A expression is increased. NKG2A recovery is inversely
correlated with CD158 recovery in the year after HSCT. This
altered phenotype includes more CD56bright cells, fewer
CD56dim NK cells, and altered CD94/NKGA expression. Acti-
vation or inhibition of NKR expression during early recon-
stitution is associated with lower levels of in vitro NKTransplantation.
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killer cell immunoglobulin-like receptors (KIRs) is inﬂuenced
by many factors, including the conditioning regimen, level of
T cell depletion, and the use of immune suppression after
transplantation, as recently reviewed by Zhao et al. [72].
Monocyte engraftment is rapid, with normal values on
day þ15 after unmanipulated haploidentical blood and BM
transplantation [25]. In HLA-identical HSCT settings, the
absolute monocyte counts at day þ30 (>300 cells/mL) are
strongly associated with improved survival [73,74], whereas
no association between monocyte recovery and outcome
after haploidentical HSCT has been reported.
Dendritic cells (DCs) are highly important antigen-
presenting cells with central roles in initiating and modu-
lating immune responses. Human peripheral blood DCs are
divided into 2 major subsets: myeloid DCs (mDCs) and
plasmacytoid DCs (pDCs). mDCs are further subdivided into 2
subsets: T helper cell (Th) 1-promoting mDCs (mDC1s) and
Th2-promoting mDCs (mDC2s) [75]. Our preliminary data
showed extremely low mDC1, mDC2, and PDC counts at 1-3
months post-HSCT, which recovered to normal values by
1 year after unmanipulated haploidentical blood and BM
transplantation [25]. A gradual increase in the DC population
after transplantation was also reported in pediatric patients
with acute leukemiawho received CD3/CD19-depleted grafts
from haploidentical donors [41]. The early delayed immune
reconstitution of DCs may contribute in part to an increased
rate of postengraftment bacterial and fungal infections [76],
although little is known about the recovery of DC function
after haploidentical transplantation [25,41].
Invariant NK T (iNKT) cells are a specialized subset of T
cells that use their T cell receptors (TCRs) to recognize self
and foreign lipids presented by CD1d as cognate antigens.
These cells can have protective or harmful roles in many
pathological states, including microbial infection, autoim-
mune disease, allergic disease, and cancer [77]. In pediatric
patients, de Lalla et al. [33] observed that iNKT recovered
slowly after CD34-selected haploidentical HSCT and reached
normal reference values by 18 months post-transplantation.
Their data also suggest that the frequency of iNKT cells is
signiﬁcantly correlated with the remission state after hap-
loidentical HSCT. In HLA-identical transplantation settings,
Chaidos et al. [78] reported that CD4(-) iNKT cell dose was
the sole graft parameter predictive of clinically signiﬁcant
acute GVHD. This interesting ﬁnding awaits conﬁrmation in
haploidentical HSCT settings.
Detailed analyses of adaptive immune reconstitution
have been performed by researchers at various trans-
plantation centers [16,17,22,25-27,29,32,33,38,41,45,79-81].
After CD34-selected haplodentical HSCT, mean (standard
deviation) CD4þ cell counts ranged from 100  40/L to
200  20/L at 10 months post-transplantation, and rose
thereafter. The mean CD8þ cell count reached 230  80/L on
day þ60, followed by a steady rise to 570  125/L by
day þ300. The mean CD16þ NK cell count reached 400/L
stably by day þ30 [38]. The recovered NK cells may enhance
the graft-versus-leukemia effect [38-82]. A German group
used negative selection of CD3/CD19 cells to retain NK cells,
monocytes, and DCs in haploidentical allografts and found
delayed T cell reconstitution, with a median of 369 CD3þ
cells/mL, 177 CD4þ cells/mL, and 193 CD8þ cells/mL on
day þ400 [8,83]. In our unmanipulated haploidentical blood
and BM transplantation protocol, a median absolute number
of 277 CD4þ T cells/mL and 884 CD8þ T cells/mL were recov-
ered at 1 year post-transplantation [25]. Immune recoveryafter unmanipulated haploidentical HSCT appears to bemore
rapid than CD34-selected haploidentical transplantation;
however, the 2 transplantation methods are not strictly
comparable [17,25,38,39].
The expansion of memory T cells (especially CD4þ mem-
ory Tcells, which reconstitute later than CD8þmemory Tcells
and relymore on thymic production of naive Tcells) results in
a signiﬁcant inversion of the CD4/CD8 ratio up to 1 year after
transplantation [25,39,41]. In contrast to most previously
reported results [25,27,36,38,39,41], no signiﬁcant inversion
of the CD4/CD8 ratio was observed after haploidentical HSCT
using reduced-intensity conditioning and CD3/CD19-
depleted grafts [17]. In the TCD haploidentical HSCT proto-
col [45], the main lymphocyte populations (including CD3þ
Tcells, CD4þ Tcells, CD8þ Tcells, and B cells) and the CD4/CD8
ratio reconstituted to age-matched control levels by 4 to
6 years post-transplantation. Similar kinetics in B cell recov-
ery have been reported by our group and others [17,25,41,84],
with absolute numbers of B cells increasing gradually and
reaching normal levels more than 1 year after HSCT.
Regarding the reconstutiton of T cell function, an inter-
esting ﬁnding is that the ability of T cells to secrete IFN and
IL-4 recovers to normal level by day þ30 post-HSCT in pa-
tients without acute GVHD, although TCR rearrangement
excision DNA circle (TREC) levels remain low for 12 to
24 months after unmanipulated haploidentical HSCT [29]. At
4 to 6 years after TCD haploidentical HSCT, recipients
demonstrate higher proportions of CD31þ naïve CD4þ T cells
compared with donors [17,45]. The signal-joint TCR excision
circle (sjTREC) levels in the recipients tend to be higher than
the levels in donors, which are similar to those seen in age-
matched control subjects.
The foregoing observations suggest that long-term T cell
reconstitution is critically inﬂuenced by de novo T cell pro-
duction, reﬂecting thymopoiesis as a central mechanism. A
skewed and restricted distribution of TCR repertoires has
been observed at less than 180 days post-transplantation
[17]. Azevedo et al. [45] reported that at 4-6 years post-
transplantation, patient CD4þ T cells and CD8þ T cells
exhibit a diverse T cell repertoire and reconstitute a diverse
regulatory T cell (Treg) pool through a mechanism involving
de novo thymic production. Their ﬁndings provide strong
evidence that a normal immune system can be reconstituted
after haploidentical HSCT; however, the small number of
patients in their study precluded from a subgroup analysis to
identify the factors inﬂuencing immune reconstitution. In
addition, the function of T cells in unmanipulated hap-
loidentical HSCT remains to be investigated in depth
[2,71,85-88].
More recently, Ciurea et al. [36] demonstrated that
compared with patients who underwent TCD haploidentical
HSCT, patients who received T cellereplete haploidentical
allografts exhibit better immune reconstitution of T cell
subsets, including CD4þ Tcells, CD8þ Tcells, naive Tcells, and
memory T cells, during the ﬁrst 6 months after trans-
plantation (Table 1). The authors suggested that improved
immune reconstitution might contribute to the improved
early outcomes observed with the use of T cellereplete grafts
[36]. Thus, a prospective study to compare immune recovery
between TCD and Tcellereplete haploidentical approaches is
warranted.
Overall, the ﬁrst 90 days after haploidentical HSCT are
characterized by persistent CD4þ and CD4þ naive T cells, B
cell lymphopenia, and low thymic function, which render
patients especially susceptible to viral and fungal infections
Table 1
Immune Reconstitution in Hapolidentical Transplantation and MSDT, MUDT, and Umbilical Cord Blood Transplantation
Federmann
et al. [17]
Chang et al. [25] Ciurea et al. [36] Pérez-Martínez et al. [41] Kesserwan
et al. [43],*
Dominietto A et al. [93],*
MSDT HBMT TCD T Cell Replete HIT MUDT ALT CBIBT HIT MSDT
No. of patients 28 25 50 33 32 15 15 21 125 103 40 176
Age, yr, median (range) 45 (19-65) 38.5 (24-57) 24.5 (7-48) 36 (18-56) 45 (20-63) 9.7  1.1 8.6  1.4 45 (29-46) NA NA NA NA
Male/female sex, n 15/13 17/8 28/22 16/17 19/13 14/1 11/4 NA NA NA NA NA
Diagnosis HM HM HM HM HM þ others AML/ALL AML/ALL HM NA NA NA NA
Myeloablative conditioning 0 Modiﬁed Bu/Cy Modiﬁed Bu/Cy þ ATG 33 26 0 0 Cy þ TBI þ Flu NA NA NA NA
Reduced-intensity conditioning Flu þ Mel þ
OKT3 þ Thi
0 0 0 6 15 15 0 NA NA NA NA
GVHD prophylaxis MMF MTX þ CSA þ MMF MTX þ CSA þ MMF ATG Cy þ Tac þ
MMF
CSA CSA Cy þ CSA þ MMF ATG CSA þ MMF CSA þ
Cy þ MMF
CSA þ MTX
Allografts CD3/CD19-
depleted G-PB
G-BM þ G-PB G-BM þ G-PB SS-BM SS-BM CD3/CD19-depleted
G-PB
SS-BM SS-BM SS-BM SS-BM SS-BM
Immune recovery, cells/L
CD3þ T cells
Day 30 post-SCT 8 at day þ40 348 135 NA NA 870 226 31 146 30 195 477
Day 90 post-SCT 205 at day þ100 1048 883 NA NA 983 652 413 at day þ60 404 57 182 565
Day 180 post-SCT 369 at day þ400 1037 1163 NA NA NA NA 691 470 196 499 700
CD3þCD4þ T cells
Day 30 post-SCT 5 at day þ40 141 21 1 26 141 138 11 36 7 45 160
Day 90 post-SCT 70 at day þ100 220 152 7 127 305 198 154 at day þ60 86 36 127 170
Day 180 post-SCT 177 at day þ400 276 163 69 194 NA NA 193 111 106 211 198
CD3þCD8þ T cells
Day 30 post-SCT 2 at day þ40 115 98 1 22 730 85 11 102 42 73 280
Day 90 post-SCT 66 at day þ100 645 672 17 181 678 447 193 at day þ60 278 16 424 389
Day 180 post-SCT 193 at day þ400 580 918 54 167 NA NA 409 413 51 408 500
CD3þCD4þ naïve cells
Day 30 post-SCT NA 90 6 0.7 3.45 3.9 5.3 0.45 NA NA NA NA
Day 90 post-SCT 28 at day þ100 152 33 0.55 7.3 3.3 3.3 9 at day þ60 NA NA NA NA
Day 180 post-SCT 115 at day þ400 196 69 4.8 6.72 NA NA 24 NA NA NA NA
CD3þCD4þ memory cells
Day 30 post-SCT NA 131 20 2.6 24 136 134 4 NA NA NA NA
Day 90 post-SCT 79 at day þ100 155 108 16 97 299 181 65 at day þ60 NA NA NA NA
Day 180 post-SCT 205 at day þ400 261 171 111 179 NA NA 48 NA NA NA NA
B cells
Day 30 post-SCT NA 13 13 5 0.95 39 24.6 0.5 NA NA NA NA
Day 90 post-SCT 100 at day þ150 33 23 55 64 147 43 119 at day þ60 NA NA NA NA
Day 180 post-SCT 275 at day þ400 60 54 58 95 NA NA 104 NA NA NA NA
NK cells
Day 30 post-SCT 248 at day þ20 NA NA 225 84 291 254 59 NA NA NA NA
Day 90 post-SCT NA NA NA 357 183 299 253 189 at day þ60 NA NA NA NA
Day 180 post-SCT NA NA NA 290 172 NA NA 168 NA NA NA NA
HBMT indicates haploidentical blood and BM transplantation; HM, hematologic malignancy; AML, acute myelogenous leukemia; ALL, acute lympoblastic leukemia; ALT, alternative donor (1 antigen-mismatched family or
unrelated donors) transplantation; CBIBT, unrelated cord blood grafted intrabone transplantation; NA, not available; Cy, cyclophosphamide; TBI, total body irradiation; Flu, ﬂudarubine; Bu, busulfan; ATG, anti-human thymocyte
immunoglobulin; Mel, melphalan; Thi, thiotepa; MMF, mycophenolate mofetil; CSA, cyclosporine A; MTX, methotrexate; Tac, tacrolimus; G-BM, G-CSFeprimed BM; G-PB, G-CSFemobilized peripheral blood stem cell grafts;
SS-BM, steady-state BM.
* Data coming from meeting abstract.
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Table 2
Effect of Recovered Immune Subsets on Outcomes after Haploidentical Transplantation
Disease (No. of Patients)
[Reference]
Allografts Conditioning
Regimen
Reconstituted Immune
Subsets
Potential Effects on Clinical
Outcomes
Hematologic malignancies (27);
other diseases (6) [23]
Selected CD34þ cells MA (33) Thymic-dependent T cells:
sjTREC <0.1/150,000T
TREC <0.001/150,000T
Low thymic function is associated
with leukemia relapse.
Hematologic malignancies (30);
other diseases (2) [90]
Unmanipulated BM (13)
and PBSCs (6); selected
CD34þ cells (13)
MA (32) CD3þCD8þ T cells Univariate analysis demonstrated
superior survival in patients with
CD8þCD3þ absolute counts above the
5th percentile of age-matched normal
levels during the ﬁrst year post-
transplantation.
Hematologic
malignancies (43) [24]
G-BM þ G-PB MA (43) CD56bright NK cells (9.27)
and T:NK ratio at day 14
post-transplantation
The patients with more CD56bright NK
cells in the recovery stage had a
higher survival rate (hazard ratio
[HR], 0.406; P¼ .017) and the patients
with a T/NK ratio >1.0 had a greater
likelihood of getting aGVHD (HR,
3.436; P ¼ .059) and chronic GVHD
(HR, 3.925; P ¼ .028).
Hematologic
malignancies (206) [18]
G-BM þ G-PB MA (206) Early recovered lymphocytes Multivariate analysis showed that
patients with higher day 30 ALC
(300/mL) was associated with low
relapse rate, low TRM, and superior
survival in both adult and pediatric
patients.
Hematologic malignancies (60) [59] G-BM þ G-PB MA (60) Early recovered lymphocytes
Hematologic malignancies (78) [60] G-BM þ G-PB MA (78) Early recovered lymphocytes
Hematologic malignancies (21) [43] SS-BM MA (21) Early recovered lymphocytes Patients with a day 30 ALC>200 cells/
mL had a markedly improved overall
survival and event-free survival.
Hematologic
malignancies (22) [33]
G-PB þ TCD MA (22) iNKT The frequency of iNKT cells was
signiﬁcantly correlated with
remission after transplantation.
Hematologic malignancies (98);
nonmalignancies (33) [61]
BM (78); G-PB (42);
umbilical cord blood (11)
MA (131) CMV-speciﬁc CD8þ T cells
(3 cytþ cells/mL); CMV-speciﬁc
CD4þ T cells (1 cytþ cells/mL)
No CMV DNAnemia was evident.
Acute leukemia (30) [41] G-PB with CD3/CD19
depletion
MA (30) Lymphoid DC2- cells A signiﬁcant correlation was seen
between the number of lymphoid
DC2- cells on day þ60 with patient
survival.
Hematologic
malignancies (89) [91]
TCD and TCR allografts MA (89) CMV-speciﬁc IFN ELISPOT
(1000 spots/mL)
Low TRM and virus reactivation were
noted.
Hematologic malignancies
(47) [63]
Unmanipulated PBSC (27);
BM (20)
Nonmyleoablative
(30); MA (17)
Treg:CD4þ T cell ratio at day
14 post-transplantation
Multivariate analysis showed that a
cutoff ratio value of 9% yielded the
most accurate predictions of future
aGVHD incidence. Treg:CD4þ T cell
ratios of <9% predicted a signiﬁcantly
higher incidence of aGVHD compared
with ratios 9% (P ¼ .0082).
PBSCs indicate peripheral blood stem cells.
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the critical importance of improving immune recovery in
both TCD and T cellereplete haploidentical HSCT settings.
ASSOCIATION OF RECOVERED IMMUNE CELLS WITH
TRANSPLANTATION OUTCOMES
A number of studies have evaluated the association of
immune recovery with clinical outcomes after haploidentical
transplantation (Table 2) [18,24,59,60]. A higher absolute
lymphocyte count at day 30 post-transplantation (ALC-30;
300 cells/mL) is associated with lower incidences of relapse
and transplantation-related mortality (TRM) and superior
leukemia-free survival and overall survival in both adult and
pediatric patients after unmanipulated haploidentical blood
and BM transplantation [18,59,60]. Using the unmanipulated
haploidentical HSCT protocol, the Peking University group
demonstrated a survival advantage for patients with high
early (day þ14) levels of CD56bright NK cells after unmanip-
ulated haploidentical HSCT [24]. In Spain, Martin et al. [89]conﬁrmed this result using unmanipulated haploidentical
BM grafts after RIC. Other factors, including lower numbers
of recovered CD3þCD8þ T cells and lymphoid mDC2 cells,
may contribute to inferior survival [41-90]. Fujioka et al. [63]
reported that a Treg:CD4þ T cell ratio <9% is predictive a
signiﬁcantly higher incidence of acute GVHD compared with
a ratio 9% (P ¼ .0082) after unmanipulated blood or BM
transplantation. This ﬁnding awaits conﬁrmation in other
haploidentical HSCT protocols, such as transplantation
with CD3/CD19-depleted allografts [8] and BM trans-
plantation with high-dose post-transplantation cyclophos-
phamide [71].
Another study investigated multiple parameters of T cell
immune reconstitution in 89 patients who underwent hap-
loidentical HSCT. Using a receiver operating characteristic
curve analysis of cytomegalovirus (CMV)-speciﬁc IFN
enzyme-linked immunosorbent spot (ELISPOT) assay results
at day 30 to 90, Noviello et al. [91] found that cutoff values of
1000 spots/mL allowed researchers to identify those patients
Y.-J. Chang et al. / Biol Blood Marrow Transplant 20 (2014) 440e449444who did not reactivate the virus at later time pointswith high
speciﬁcity (>95%). Strikingly, the 2-year TRM rate was 32%
in patients with an ELISPOT ﬁnding of <1000 spots/mL and
0% in those with >1000 spots/mL (P < .05). This interesting
ﬁnding warrants the use of a predictive biomarker in larger
multicenter series to investigate whether a CMV-speciﬁc
IFN- ELISPOT cutoff value of 1000 spots/mL is a strong
surrogate biomarker for TRM. When Clave et al. [23] evalu-
ated thymic function in a group of pediatric recipients, they
found that 6 months after CD34-selected HLA-haploidentical
HSCT, a TREC value below the limit of detection (<0.1 per
150,000 CD3þ T cells for sjTREC and <0.001 per 150,000
CD3þ T cells for TREC) was associated with an increased risk
of relapse [23].
In summary, prospective studies with larger patient
populations are needed to draw deﬁnitive conclusions
regarding the impact of recovered immune cells on clinical
outcomes in T cellereplete and TCD nonmyeloablative or
myeloablative haploidentical settings [3,8,92]. These studies
are important to the prediction of such clinical outcomes as
infection rates, relapse, and TRM [37,62]. Shimoni [62] sug-
gested that the ALC-30 has long been a simple test of im-
mune recovery that can predict outcome after autologous
HSCT as well as allogeneic and haploidentical HSCT
[18,59,60]. It is easy, reproducible, and requires no special
expertise. Thus, the measurement of ALC-30 may have
practical signiﬁcance in applying interventions to facilitate
immune reconstitution as described previously for hap-
loidentical transplants [18,42,59,60].
COMPARISION OF IMMUNE RECOVERY BETWEEN
HAPLODENTICAL AND OTHER TRANSPLANTATION
MODALITIES OR GRAFT OPTIONS
Several published prospective and retrospective studies
have highlighted the differences in immune reconstitution
after unmanipulated haploidentical HSCT versus HLA-
matched sibling donor transplantation (MSDT), matched
unrelated donor transplantation (MUDT), or umbilical cord
blood transplantation (Table 1). Chang et al. [25] found that
compared with HLA-matched recipients, haploidentical re-
cipients had lower counts of T cells (particularly CD4 T cells)
and DC subsets before day þ90, as well as greater CD28
expression on CD4þ and CD8þ T cells, whereas T cells were
equally functional in the 2 patient groups at day þ30. In
addition, Dominietto et al. [93] recently demonstrated early
delayed immune reconstitution after haploidentical trans-
plantation (HIT) compared with MSDT [93]. Several lines of
evidence suggest an association between improved immune
recovery and better transplantation outcomes [13,24,94-96];
however, in our center, transplantation outcomes regarding
overall survival and leukemia-free survival were comparable
after HIT and MSDT, although unmanipulated HIT was char-
acterized by delayed early reconstitution of T cells and DCs,
as well as a higher incidence of CMV antigenemia [86,87].
Several factors may account for this ﬁnding. Compensatory
expansion of monocytes, NK cells, and cytotoxic T lympho-
cytes (CTLs) [25], especially CMV-pp65 peptide-speciﬁc CTLs
with the central memory CD45ROþCD62Lþ cell phenotype,
accompanies the recovery of CD8þ T cells. This cell popula-
tion may proliferate and differentiate into effector memory T
cells stimulated with CMV antigen and may contribute to a
reduced incidence of CMV disease [31,47]. Other possible
contributing factors include the preemptive management of
CMV antigenemia, a superior graft-versus-leukemia effect
associated with transplantation of haploidentical versusHLA-identical sibling donor grafts for high-risk acute leuke-
mia [97], and improvements in minimal residual dis-
easeedirected relapse prophylaxis using modiﬁed donor
lymphocyte infusion [66,98-100].
In a detailed prospective analysis of immune reconstitu-
tion in MUDT and HIT with CD3/CD19-depleted grafts in 30
pediatric patients, Pérez-Martínez et al. [41] found more
rapid CD8 and CD8 memory T cell recovery during the ﬁrst
month in HIT compared with MUDT (730  208 versus
85  37 cells/mL and 723  274 versus 83  29 cells/mL,
respectively; P < .05). CD80 expression in the DC1-DC2-
subset was higher in HIT patients than the CD80 expression
in the DC1-DC2- subset in MUDT patients during the ﬁrst
2 months after HSCT (respectively, 26  6.98 vs 5  1.4/mL,
P ¼ .04 and 28  12 vs 2  0.8/mL, P ¼ .05); however, the
reconstitution of NKT cells, NK cells, and B cells was compa-
rable in the 2 groups [41]. Szabolcs et al. [101] reported an
association between CD8þ lymphocytosis and effector
memory phenotype and IFN secretion in children who
developed de novo opportunistic infections. Brown et al.
[102] presented data on recent thymic emigrants and CMV-
speciﬁc immune responses demonstrating associations be-
tween higher TREC and CMV-speciﬁc immune responses and
improved survival. Sauter et al. [103] found that an ATG-free
regimen after double cord blood transplantation could result
in more rapid CD4þ T lymphocyte reconstitution, and re-
ported no infection-related deaths after dayþ120, suggesting
a correlation between immune recovery and infection-
related death. Continuing new insights into the mecha-
nisms underlying differences in the kinetics of immune
reconstitution after HITcomparedwithMSDTandMUDTmay
help guide the design of useful strategies to accelerate im-
mune recovery in HIT settings.
STRATEGIES TO IMPROVE IMMUNE RECONSTITUTION
AFTER HAPLOIDENTICAL HSCT
Many of the currently available approaches to accelerating
immune recovery, including IL-7, keratinocyte growth factor,
growth hormone, and adoptive transfer of immune cell sub-
sets, have been reviewed elsewhere [12,19,37,66,104-106].
Here we discuss only recent informative updated trials and
reports (Table 3); data reported between 2012 and 2013)
regarding the promotion of immune reconstitution, particu-
larly in haploidentical transplantation settings [53,65,69,107].
Cytokines
IL-7
Among the cytokines used to enhance T cell reconstitu-
tion, IL-7 certainly tops the list. In a phase 1 trial, Perales et al.
[65] treated 12 patients who underwentMSDTorMUDTwith
escalating weekly doses of IL-7 for a 3-week period. Three
patients received 10 mg/kg, 6 patients received 20 mg/kg, and
3 patients received 30 mg/kg. IL-7 was well tolerated overall,
with only 1 patient developing acute skin GVHD. Compared
with baseline values, levels of recovered CD3þ, CD4þ, and
CD8þ Tcells increased by 4.3-, 6.1-, and 4.3-fold, respectively.
IL-7 also enhanced functional T cell responses and TCR di-
versity. Unfortunately, IL-7 appeared to have no signiﬁcant
effect on CD4þCD25þFoxP3þ T cells, NK cells, or B cells,
although the data that IL-7 signiﬁcantly enhances T cell re-
covery are exciting [65]. Based on the foregoing ﬁndings,
other approaches applied alone or in combination with IL-7
to promote the reconstitution of all immune subsets merit
investigation in both HLA-matched and haploidentical
transplantation protocols [2,3,87,88].
Table 3
Recent Informative* Trials and Reports Regarding Strategies for Enhancing Immune Recovery
Strategy Transplantation
Protocol
Key Points Reference
Approaches used in preclinical model
IL-15 HIT mice model IL-15 can be used for enhancing antileukemia effect of
haploidentical HSCT, which requires presence of donor-
derived T cells, especially CD8þ T cells.
Sauter et al. 2013 [58]
Depletion of naive lymphocyte
with Fas ligand
HIT mice model The proposed approach eliminates severe GVHD in T cell
ereplete transplants, preserves the tumor lytic activity of
mismatched donor T cells, maintains T cell reactivity to
third-party antigens, and, facilitates HSC engraftment.
Askenasy et al. 2013 [49]
Approaches used in clinical trial
or report
IL-7 MRDT and MUDT Treatment 12 patients with IL-7 increases T cell recovery,
induces T cell responses, and enhances TCR diversity. IL-7
have no signiﬁcant effect on Treg, NK or B cells.
Perales et al. 2012 [65]
Escalating-dose DLI HIT This study suggests that DLI, using an excalating-dose
regimen, can be safely given to mismatched transplant
recipients with a high rate of molecular remission and a low
risk of GVHD.
Innes et al. 2013 [55]
Modiﬁed DLI HIT and MRDT Eight hundred and fourteen patients were enrolled, this
study suggest that risk stratiﬁcation-directed modiﬁed DLI
may reduce relapse and improve survival of subjects with
standard-risk acute leukemia after HSCT, although the effect
of DLI on immune reconstitution need to be investigated.
Yan et al. 2012 [98]
Preemptive immunotherapy
with NK cells
HIT In this prospective phase Ⅱ study, the results suggest that
NK cell activation/expansion may be required to attain
clinical beneﬁt, while careful considerationmust be given to
the number of T cells infused.
Stern et al. 2013 [108]
Adoptive transfer of suicide
gene-tranduced donor T cells
HIT Thymopoiesis is reactivated after the infusion of gene-
modiﬁed lymphocytes, enhancing the generation of a
protective T cell compartment that is able to reduce the
incidence of infectious and control of GVHD.
Vaglo et al. 2012 [65]
Adoptive transfer of donor-derived
CMV-speciﬁc T cells
HIT, MSDT, and MUDT Infusion of CMV-speciﬁc T cell early posttransplant reduced
the need for pharmacotherapy without increased rates of
CMV-related organ damage and increasing acute and
chronic GVHD.
Blyth et al. 2012 [69]
Adoptive transfer of trivirus-directed
T cells
HIT, MSDT, and MUDT In ten patients, trivirus-directed T cells administration
produced completed virological responses in 80% cases and
a decrease in viral load was associated with an increase in
the frequency of T cell directed against the infecting virus.
No toxicities were observed.
Gerdemman et al. 2013 [63]
MRDT indicates HLA-matched related donor transplantation; DLI, donor lymphocyte infusion.
* Published between 2012 and 2013.
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Using a clinically relevant haploidentical murine trans-
plantation model, Sauter et al. [58] found that IL-15
administration signiﬁcantly increased CD8þ T cell and NK
cell reconstitution and also improved graft-versus-leuke-
mia/graft-versus-tumor activity in recipients of hap-
loidentical HSCT. These authors also demonstrated that
IL-15 increased intracellular IFN secretion in undivided
and slowly proliferating CD8þ T cells in recipients of car-
boxyﬂuoresceinsuccinimidyl esterelabeled T cells, with no
change in the IFN-secreting alloreactive/rapidly prolifera-
tive cell population [58].
The efﬁciency, safety, and feasibility of using IL-
15estimulated CD3/CD19-depleted stem cells or IL-
15eactivated cytokine-induced killer cells to treat relapse
after haploidentical transplantation have been investigated,
albeit only in small patient populations [51,57]. Pfeiffer et al.
[57] reported that in 8 patients, recovered CD56þ, CD3þ/CD4þ,
and CD3þ/CD8þ lymphocyte counts at 15 to 30 days after
receipt of IL-15estimulated stem cell boosts were similar to or
even higher than those before the initiation of chemotherapy.
Preemptive Transfer of NK Cells
Adoptive immunotherapy with allogeneic puriﬁed NK cell
products might exert graft-versus-tumor alloreactivity with
little risk of GVHD. In a prospective phase 2 study, Stern et al.[108] administered puriﬁed NK cell products to high-risk
patients treated with haploidentical TCD HSCT. Sixteen pa-
tients received a total of 29 NK cell infusions on
days þ3, þ40, and þ100 post-transplantation. The median
dose of infused NK cells per product was 1.21107/kg (range,
0.3-3.8  107/kg). Four of the 16 patients were alive at the
time of this report, at a median follow-up of 5.8 years. Rapid
reconstitution of lymphocyte subsets at day þ100 was
observed, with a median CD8 T cell count of 266 cells/mL and
a median CD4 T cell count of 181 cells/mL. These promising
results warrant further study to determine the optimal dose
and timing of NK cell immunotherapy for antileukemia
activity.
Genetically Modiﬁed Donor T Cell Infusion
Several researchers have investigated the use of suicide
geneetransduced donor T cells to enhance immune recon-
stitution while controlling GVHD. In a multicenter phase
1/2 clinical trial, puriﬁed herpes simplex thymidine kinase
suicide geneetransduced donor T cells (TKpos cells) were
infused serially into 28 adult patients with a hematologic
malignancy after CD34-selected haploidentical trans-
plantation [70]. Twenty-two of the 28 patients who received
the puriﬁed TKpos cells exhibited a rapid recovery of T cells
associated with a concomitant improvement in clinical out-
comes and reduced TRM. Patients who did not receive TKpos
Figure 1. A proposed prognostic immune subsetedirected strategy to improve immune reconstitution after HIT. On day 0, in vitro alloreactive T celleand/or B
celledepleted allografts, including NK cells, HSCs, Tregs, and myeloid-derived suppressor cells (MDSCs), were infused to the recipients who received a conditioning
regimen to decrease the incidence of GVHD and enhance immune reconstitution. After transplantation, the kinetics of immune recovery were monitored. For patients
with rapid immune recovery (as demonstrated by ALC-30  300/mL or another parameter predictive of rapid immune recovery), no interventions were required, and
immune reconstitution was monitored only. For patients with delayed immune recovery (ALC-30 < 300/mL or other parameters predictive of delayed immune re-
covery), interventions, including IL-7 and/or adoptive transfer of expanded progenitor T cells or virus-speciﬁc donor T cells, were implemented to improve immune
reconstitution. MHC, major histocompatibility complex.
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rienced dismal outcomes, owing mainly to infectious com-
plications. Impressively, further follow-up of these patients
revealed that transfer of TKpos cells not only enhanced the
regeneration of CD3þ T cells, but also increased counts of the
CD4þ T cell subset and the T cell subset with a naive
phenotype (CD62LþCD45RAþCD31þ), as well as sjTREC
counts, in parallel to the increase in the naive T cell subset.
Strikingly, an increase in serum IL-7 level was observed early
after the TKpos T cell add-back, followed by a concomitant
rise in peripheral T cell counts. Computed tomogra-
phyebased analysis revealed an increase in thymic tissue
even in elderly patients. Additional experiments demon-
strated that the antiviral activity of the newly generated
T cells was fully maintained.
The biological mechanism responsible for these unex-
pected ﬁndings is unclear. The transient increase in IL-7
might be a contributing factor, as described by Perales et al.
[65] in a phase 1 trial, but is likely insufﬁcient to induce long-
lasting thymopoiesis. The ﬁndings of Vago et al. [70] might
suggest new approaches to accelerating immune reconsti-
tution in patients not only after haploidentical trans-
plantation of CD34þ stem cells, but also in other
transplantation settings, and particularly in elderly patients
[2,3,67,71,88].
Adoptive Transfer of Pathogen-Speciﬁc T Cells
Gerdemann et al. [49] recently developed a new rapid and
simpliﬁedmanufacturing strategy inwhich DCs nucleofected
with DNA plasmids encoding a range of immunodominant
and subdominant viral antigens from adenovirus (Adv),
CMV, or Epstein-Barr virus (EBV) are used to generate
trivirus-speciﬁc T cells. In a recent study, trivirus-directedT cells were administered to recipients of haploidentical
(n ¼ 5), matched unrelated (n ¼ 3), mismatched unrelated
(n ¼ 1), or matched related (n ¼ 1) transplants with active
CMV (n ¼ 3), Adv (n ¼ 1), EBV (n ¼ 2), EBV þ Adv (n ¼ 2), or
CMV þ Adv (n ¼ 2) infections. The cells produced complete
virologic responses in 80% of recipients, including all patients
with dual infections. In each case, a decrease in viral load was
correlated with an increase in the frequency of T cells
directed against the infecting virus(es); both immediate and
delayed toxicities were absent [68]. The authors suggested
that a DNA plasmid-based approach might increase both the
feasibility and applicability of T cell therapy.
Little data are available on vaccine responses in patients
undergoing HIT [109]. More recently, several other ap-
proaches, including the depletion of naive lymphocytes us-
ing Fas ligand [53] and the infusion of CD62L- memory T cells
[107], have been used in preclinical models to enhance im-
mune reconstitution after transplantation. Additional studies
are warranted to investigate whether these preclinical ap-
proaches can be translated into clinical trials.
FUTURE DIRECTIONS
Delayed immune reconstitution is an important issue in
haploidentical HSCT. Substantial progress has been made in
the ﬁeld, including insight into recovered immune subsets
that can predict outcomes and new strategies for accelerating
immune recovery. These advances make it possible to
establish a prognostic immune subsetedirected strategy to
improve immune recovery in haploidentical settings
(Figure 1). To achieve this goal, prospective, multicenter trials
are needed to investigate whether a low ALC-30 or other
simple immune parameters can be used to identify which
patients should be treated to improve immune recovery. In
Y.-J. Chang et al. / Biol Blood Marrow Transplant 20 (2014) 440e449 447addition, pilot studies should be conducted to evaluate the
most effective immune reconstitution-accelerating strategy
or combination of approaches. Although promising survival
has been achieved with the establishment of many hap-
loidentical transplantation protocols, we believe that a
predictive immune subseteguided strategy to accelerate
immune recovery might further improve transplantation
outcomes in the future, making haploidentical trans-
plantation a routine strategy for patients requiring HSCT.ACKNOWLEDGMENTS
The authors would like to express their apologies to those
whose important work was not cited in this review. They
thank San Francisco Edit (www.sefedit.net) for their assis-
tance in editing the manuscript.
Financial disclosure: Support was provided by the Key
Program of the National Natural Science Foundation of China
(Grant 81230013), the Chang Jiang Scholars Program, and the
Bejing Municipal Science and Technology Commission
(Grants Z121107002612035 and Z121107002812033).
Conﬂict of interest statement: There are no conﬂicts of in-
terest to report.REFERENCES
1. Bashey A, Zhang X, Sizemore CA, et al. T cellereplete HLA-
haploidentical hematopoietic transplantation for hematologic
malignancies using post-transplantation cyclophosphamide results
in outcomes equivalent to those of contemporaneous HLA-matched
related and unrelated donor transplantation. J Clin Oncol. 2013;31:
1310-1316.
2. Di Bartolomeo P, Santarone S, De Angelis G, et al. Haploidentical,
unmanipulated, G-CSFeprimed bone marrow transplantation for pa-
tients with high-risk hematologic malignancies. Blood. 2013;121:
849-857.
3. Dvorak CC, Gilman AL, Horn B, et al. Haploidentical related-donor
hematopoietic cell transplantation in children using megadoses of
CliniMACs-selected CD34(þ) cells and a ﬁxed CD3(þ) dose. Bone
Marrow Transplant. 2013;48:508-513.
4. Chang Y-J, Huang X-J. Haploidentical bone marrow transplantation
without T cell depletion. Semin Oncol. 2012;39:653-663.
5. Bolanos-Meade J, Fuchs EJ, Luznik L, et al. HLA-haploidentical bone
marrow transplantation with posttransplant cyclophosphamide ex-
pands the donor pool for patients with sickle cell disease. Blood. 2012;
120:4285-4291.
6. Im HJ, Koh KN, Choi ES, et al. Excellent outcome of haploidentical
hematopoietic stem cell transplantation in children and adolescents
with acquired severe aplastic anemia. Biol Blood Marrow Transplant.
2013;19:754-759.
7. Wang Y, Liu DH, Liu KY, et al. Long-term follow-up of haploidentical
hematopoietic stem cell transplantation without in vitro T cell
depletion for the treatment of leukemia: nine years of experience at a
single center. Cancer. 2013;119:978-985.
8. Federmann B, Bornhauser M, Meisner C, et al. Haploidentical alloge-
neic hematopoietic cell transplantation in adults using CD3/CD19
depletion and reduced intensity conditioning: a phase II study. Hae-
matologica. 2012;97:1523-1531.
9. Reisner Y, Hagin D, Martelli MF. Haploidentical hematopoietic trans-
plantation: current status and future perspectives. Blood. 2011;118:
6006-6017.
10. Krenger W, Blazar BR, Hollander GA. Thymic T-cell development in
allogeneic stem cell transplantation. Blood. 2011;117:6768-6776.
11. Geddes M, Storek J. Immune reconstitution following hematopoietic
stem-cell transplantation. Best Pract Res Clin Haematol. 2007;20:329-348.
12. Seggewiss R, Einsele H. Immune reconstitution after allogeneic
transplantation and expanding options for immunomodulation: an
update. Blood. 2010;115:3861-3868.
13. Bosch M, Khan FM, Storek J. Immune reconstitution after hemato-
poietic cell transplantation. Curr Opin Hematol. 2012;19:324-335.
14. Toubert A, Glauzy S, Douay C, Clave E. Thymus and immune recon-
stitution after allogeneic hematopoietic stem cell transplantation in
humans: never say never again. Tissue Antigens. 2012;79:83-89.
15. Mackall C, Fry T, Gress R, et al. Background to hematopoietic cell
transplantation, including post-transplant immune recovery. Bone
Marrow Transplant. 2009;44:457-462.
16. Pfeiffer MM, Feuchtinger T, Teltschik HM, et al. Reconstitution of
natural killer cell receptors inﬂuences natural killer activity andrelapse rate after haploidentical transplantation of T- and B-
celledepleted grafts in children. Haematologica. 2010;95:1381-1388.
17. Federmann B, Hagele M, Pfeiffer M, et al. Immune reconstitution after
haploidentical hematopoietic cell transplantation: impact of reduced-
intensity conditioning and CD3/CD19-depleted grafts. Leukemia.
2011;25:121-129.
18. Chang Y-J, Zhao X-Y, Huo MR, et al. Inﬂuence of lymphocyte recovery
on outcome of haploidentical transplantation for hematologic ma-
lignancies. Medicine. 2009;88:322-330.
19. Oevermann L, Lang P, Feuchtinger T, et al. Immune reconstitution and
strategies for rebuilding the immune system after haploidentical stem
cell transplantation. Ann NY Acad Sci. 2012;1266:161-170.
20. Isgro A, Marziali M, Sodani P, et al. Immunohematologic reconstitu-
tion in pediatric patients after T celledepleted HLA-haploidentical
stem cell transplantation for thalassemia. Biol Blood Marrow Trans-
plant. 2010;16:1557-1566.
21. Dror Y, Gallagher R, Wara DW, et al. Immune reconstitution in severe
combined immunodeﬁciency disease after lectin-treated, T-cellede-
pleted haplocompatible bone marrow transplantation. Blood. 1993;
81:2021-2030.
22. Chen X, Hale GA, Barﬁeld R, et al. Rapid immune reconstitution after a
reduced-intensity conditioning regimen and a CD3-depleted hap-
loidentical stem cell graft for paediatric refractory haematological
malignancies. Br J Haematol. 2006;135:524-532.
23. Clave E, Lisini D, Douay C, et al. A low thymic function is associated
with leukemia relapse in children given T-celledepleted HLA-
haploidentical stem cell transplantation. Leukemia. 2012;26:
1886-1888.
24. Chang Y-J, Zhao X-Y, Huang X-J. Effects of the NK cell recovery on
outcomes of unmanipulated haploidentical blood and marrow
transplantation for patients with hematologic malignancies. Biol Blood
Marrow Transplant. 2008;14:323-334.
25. Chang Y-J, Zhao X-Y, Huo MR, et al. Immune reconstitution following
unmanipulated HLA-mismatched/haploidentical transplantation
compared with HLA-identical sibling transplantation. J Clin Immunol.
2012;32:268-280.
26. Haddad E, Landais P, Friedrich W, et al. Long-term immune recon-
stitution and outcome after HLA-nonidentical T-celledepleted bone
marrow transplantation for severe combined immunodeﬁciency: a
European retrospective study of 116 patients. Blood. 1998;91:
3646-3653.
27. Friedrich W, Honig M, Schulz A, Muller SM. Immune reconstitution in
congenital disorders after HLA-haploidentical hemopoietic stem cell
transplantation. Blood Cells Mol Dis. 2004;33:291-293.
28. Nguyen S, Dhedin N, Vernant JP, et al. NK-cell reconstitution after
haploidentical hematopoietic stem-cell transplantations: immaturity
of NK cells and inhibitory effect of NKG2A override GvL effect. Blood.
2005;105:4135-4142.
29. Fu YW, Wu DP, Cen JN, et al. Patterns of T-cell reconstitution by
assessment of T-cell receptor excision circle and T-cell receptor clonal
repertoire after allogeneic hematopoietic stem cell transplantation in
leukemia patients: a study in Chinese patients. Eur J Haematol. 2007;
79:138-145.
30. Rizzieri DA, Koh LP, Long GD, et al. Partially matched, non-
myeloablative allogeneic transplantation: clinical outcomes and im-
mune reconstitution. J Clin Oncol. 2007;25:690-697.
31. Luo XH, Huang X-J, Liu KY, et al. Protective immunity transferred by
infusion of cytomegalovirus-speciﬁc CD8(þ) T cells within donor
grafts: its associations with cytomegalovirus reactivation following
unmanipulated allogeneic hematopoietic stem cell transplantation.
Biol Blood Marrow Transplant. 2010;16:994-1004.
32. Bader P, Soerensen J, Jarisch A, et al. Rapid immune recovery and low
TRM in haploidentical stem cell transplantation in children and
adolescence using CD3/CD19-depleted stem cells. Best Pract Res Clin
Haematol. 2011;24:331-337.
33. de Lalla C, Rinaldi A, Montagna D, et al. Invariant NKT cell recon-
stitution in pediatric leukemia patients given HLA-haploidentical
stem cell transplantation deﬁnes distinct CD4þ and CD4- subset
dynamics and correlates with remission state. J Immunol. 2011;186:
4490-4499.
34. Grosso D, Carabasi M, Filicko-O’Hara J, et al. A 2-step approach to mye-
loablative haploidentical stem cell transplantation: a phase 1/2 trial
performed with optimized T-cell dosing. Blood. 2011;118:4732-4739.
35. Marcenaro E, Carlomagno S, Pesce S, et al. Role of alloreactive
KIR2DS1(þ) NK cells in haploidentical hematopoietic stem cell
transplantation. J Leukocyte Biol. 2011;90:661-667.
36. Ciurea SO, Mulanovich V, Saliba RM, et al. Improved early outcomes
using a T cellereplete graft compared with T celledepleted hap-
loidentical hematopoietic stem cell transplantation. Biol Blood Marrow
Transplant. 2012;18:1835-1844.
37. van Den Brink M, Leen AM, Baird K, et al. Enhancing immune
reconstitution: from bench to bedside. Biol Blood Marrow Transplant.
2013;19(1 Suppl):S79-S83.
38. Aversa F, Terenzi A, Tabilio A, et al. Full haplotype-mismatched he-
matopoietic stem-cell transplantation: a phase II study in patients
Y.-J. Chang et al. / Biol Blood Marrow Transplant 20 (2014) 440e449448with acute leukemia at high risk of relapse. J Clin Oncol. 2005;23:
3447-3454.
39. Ding L, Zheng XL, Dong L, et al. Analysis of T lymphocyte absolute
number and function in the early phase after haploidentical he-
matopoietic stem cell transplantation. J Exp Hematol. 2013;21:
702-706.
40. Zhao X-Y, Huang X-J, Liu KY, et al. Prognosis after unmanipulated
HLA-haploidentical blood and marrow transplantation is correlated to
the numbers of KIR ligands in recipients. Eur J Haematol. 2007;78:
338-346.
41. Perez-Martinez A, Gonzalez-Vicent M, Valentin J, et al. Early evaluation
of immune reconstitution following allogeneic CD3/CD19-depleted
grafts from alternative donors in childhood acute leukemia. Bone
Marrow Transplant. 2012;47:1419-1427.
42. Ciurea SO, Mulanovich V, Jiang Y, et al. Lymphocyte recovery predicts
outcomes in cord blood and T celledepleted haploidentical stem cell
transplantation. Biol Blood Marrow Transplant. 2011;17:1169-1175.
43. Kesserwan C, Munchel A, Kos F, et al. Immune reconstitution after
nonmyeloablative, T-cellereplete, HLA-haploidentical BMT with post-
transplantation cyclophosphamide [abstract]. Biol Blood Marrow
Transplant. 2011;17:S230.
44. Lang P, Feuchtinger TF, Schlegel P, et al. A new dosing scheme of ATG-F
prevents rejection and maintains immune recovery in haploidentical T
and B celledepleted stem cell transplantation. ASH Annual Meeting
Abstracts. Blood. 2012;120:4154.
45. Azevedo RI, Soares MV, Albuquerque AS, et al. Long-term immune
reconstitution of naive and memory T cell pools after haploidentical
hematopoietic stem cell transplantation. Biol Blood Marrow Trans-
plant. 2013;19:703-712.
46. Jain N, Liu H, Artz AS, et al. Immune reconstitution after combined
haploidentical and umbilical cord blood transplant. Leuk Lymphoma.
2013;54:1242-1249.
47. Luo XH, Huang X-J, Li D, et al. Immune reconstitution to cytomega-
lovirus following partially matched-related donor transplantation:
impact of in vivo T-cell depletion and granulocyte colony-stimulating
factoreprimed peripheral blood/bone marrow mixed grafts. Trans-
plant Infect Dis. 2013;15:22-33.
48. Sanchez-Dominguez R, Pereira-Mendez S, Gomez A, et al. Notch sig-
nals contribute to preserve the multipotentiality of human CD34(þ)
CD38(-)CD45RA(-)CD90(þ) hematopoietic progenitors by maintain-
ing T cell lineage differentiation potential. Exp Hematol. 2012;40:
983-993.e4.
49. Gerdemann U, Keirnan JM, Katari UL, et al. Rapidly generated
multivirus-speciﬁc cytotoxic T lymphocytes for the prophylaxis and
treatment of viral infections. Mol Ther. 2012;20:1622-1632.
50. Gerdemann U, Vera JF, Rooney CM, Leen AM. Generation of
multivirus-speciﬁc T cells to prevent/treat viral infections after allo-
geneic hematopoietic stem cell transplant. J Vis Exp. 2011;51:2736.
51. Rettinger E, Bonig H, Wehner S, et al. Feasibility of IL-15eactivated
cytokine-induced killer cell infusions after haploidentical stem cell
transplantation. Bone Marrow Transplant. 2013;48:1141-1143.
52. Di Ianni M, Falzetti F, Carotti A, et al. Tregs prevent GVHD and pro-
mote immune reconstitution in HLA-haploidentical transplantation.
Blood. 2011;117:3921-3928.
53. Askenasy N, Mizrahi K, Ash S, et al. Depletion of naive lymphocytes
with fas ligand ex vivo prevents graft-versus-host disease without
impairing T cell support of engraftment or graft-versus-tumor activ-
ity. Biol Blood Marrow Transplant. 2013;19:185-195.
54. Wils EJ, Aerts-Kaya FS, Rombouts EJ, et al. Keratinocyte growth factor
and stem cell factor to improve thymopoiesis after autologous CD34þ
cell transplantation in rhesus macaques. Biol Blood Marrow Transplant.
2012;18:55-65.
55. Innes AJ, Beattie R, Sergeant R, et al. Escalating-dose HLA-mismatched
DLI is safe for the treatment of leukaemia relapse following
alemtuzumab-based myeloablative allo-SCT. Bone Marrow Transplant.
2013;48:1324-1328. http://dx.doi.org/10.1038/bmt.2013.69.
56. Perruccio K, Topini F, Tosti A, et al. Optimizing a photoallodepletion
protocol for adoptive immunotherapy after haploidentical SCT. Bone
Marrow Transplant. 2012;47:1196-1200.
57. Pfeiffer MM, Schumm M, Muller I, et al. IL-15estimulated CD3/CD19-
depleted stem-cell boosts in relapsed pediatric patients after hap-
loidentical SCT. Leukemia. 2012;26:2435-2439.
58. Sauter CT, Bailey CP, Panis MM, et al. Interleukin-15 administration
increases graft-versus-tumor activity in recipients of haploidentical
hematopoietic SCT. Bone Marrow Transplant. 2013;48:1237-1242.
59. Chang Y-J, Zhao X-Y, Huo MR, et al. Clinical impact of absolute
lymphocyte count on day 30 after unmanipulated haploidentical
blood and marrow transplantation for pediatric patients with hema-
tological malignancies. Am J Hematol. 2011;86:227-230.
60. Chang Y-J, Zhao X-Y, Xu LP, et al. Early lymphocyte recovery predicts
superior overall survival after unmanipulated haploidentical blood
and marrow transplant for myelodysplastic syndrome and acute
myeloid leukemia evolving from myelodysplastic syndrome. Leuk
Lymphoma. 2013;54:2671-2677.61. Lilleri D, Gerna G, Zelini P, et al. Monitoring of human cytomegalo-
virus and virus-speciﬁc T-cell response in young patients receiving
allogeneic hematopoietic stem cell transplantation. PloS ONE. 2012;7:
e41648.
62. Shimoni A. Haplo-identical stem-cell transplantation: the challenge of
immune reconstitution. Leuk Lymphoma. 2013;54:2579-2580.
63. Fujioka T, Tamaki H, Ikegame K, et al. Frequency of CD4(þ)FOXP3(þ)
regulatory T-cells at early stages after HLA-mismatched allogeneic
hematopoietic SCT predicts the incidence of acute GVHD. Bone
Marrow Transplant. 2013;48:859-864.
64. Feuchtinger T, Opherk K, Bethge WA, et al. Adoptive transfer of pp65-
speciﬁc T cells for the treatment of chemorefractory cytomegalovirus
disease or reactivation after haploidentical and matched unrelated
stem cell transplantation. Blood. 2010;116:4360-4367.
65. Perales MA, Goldberg JD, Yuan J, et al. Recombinant human
interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem
cell transplantation. Blood. 2012;120:4882-4891.
66. Chang Y-J, Huang X-J. Donor lymphocyte infusions for relapse after
allogeneic transplantation: when, if and for whom? Blood Rev. 2013;
27:55-62.
67. Ciceri F, Bonini C, Stanghellini MT, et al. Infusion of suicide-gene-
eengineered donor lymphocytes after family haploidentical haemo-
poietic stem-cell transplantation for leukaemia (the TK007 trial): a
non-randomised phase I-II study. Lancet Oncol. 2009;10:489-500.
68. Gerdemann U, Katari UL, Papadopoulou A, et al. Safety and clinical
efﬁcacy of rapidly-generated trivirus-directed T cells as treatment for
adenovirus, EBV and CMV infections after allogeneic hematopoietic
stem cell transplant. Mol Ther. 2013;21:2113-2121.
69. Blyth E, Clancy L, Simms R, et al. Donor-derived CMV-speciﬁc T cells
reduce the requirement for CMV-directed pharmacotherapy after
allogeneic stem cell transplantation. Blood. 2013;121:3745-3758.
70. Vago L, Oliveira G, Bondanza A, et al. T-cell suicide gene therapy
prompts thymic renewal in adults after hematopoietic stem cell
transplantation. Blood. 2012;120:1820-1830.
71. Luznik L, O’Donnell PV, Symons HJ, et al. HLA-haploidentical bone
marrow transplantation for hematologic malignancies using non-
myeloablative conditioning and high-dose, posttransplantation
cyclophosphamide. Biol Blood Marrow Transplant. 2008;14:641-650.
72. Zhao X-Y, Chang Y-J, Huang X-J. Conﬂicting impact of alloreactive NK
cells on transplantation outcomes after haploidentical transplantation:
do the reconstitution kinetics of natural killer cells create these dif-
ferences? Biol Blood Marrow Transplant. 2011;17:1436-1442.
73. Thoma MD, Huneke TJ, DeCook LJ, et al. Peripheral blood lymphocyte
and monocyte recovery and survival in acute leukemia post-
myeloablative allogeneic hematopoietic stem cell transplant. Biol
Blood Marrow Transplant. 2012;18:600-607.
74. DeCook LJ, Thoma M, Huneke T, et al. Impact of lymphocyte and
monocyte recovery on the outcomes of allogeneic hematopoietic SCT
with ﬂudarabine and melphalan conditioning. Bone Marrow Trans-
plant. 2013;48:708-714.
75. Chang CC, Wright A, Punnonen J. Monocyte-derived CD1aþ and CD1a-
dendritic cell subsets differ in their cytokine production proﬁles,
susceptibilities to transfection, and capacities to direct Th cell differ-
entiation. J Immunol. 2000;165:3584-3591.
76. Sun YQ, Xu LP, Liu DH, et al. The incidence and risk factors of invasive
fungal infection after haploidentical haematopoietic stem cell trans-
plantation without in vitro T-cell depletion. Clin Microbiol Infect. 2012;
18:997-1003.
77. Brennan PJ, Brigl M, Brenner MB. Invariant natural killer T cells: an
innate activation scheme linked to diverse effector functions. Nat Rev
Immunol. 2013;13:101-117.
78. Chaidos A, Patterson S, Szydlo R, et al. Graft invariant natural killer T-
cell dose predicts risk of acute graft-versus-host disease in allogeneic
hematopoietic stem cell transplantation. Blood. 2012;119:5030-5036.
79. Clave E, Lisini D, Douay C, et al. Thymic function recovery after un-
related donor cord blood or T-celledepleted HLA-haploidentical stem
cell transplantation correlates with leukemia relapse. Front Immunol.
2013;4:54.
80. Sivori S, Carlomagno S, Falco M, et al. Natural killer cells expressing
the KIR2DS1-activating receptor efﬁciently kill T-cell blasts and
dendritic cells: implications in haploidentical HSCT. Blood. 2011;117:
4284-4292.
81. Xiao TZ, Singh K, Dunn E, et al. T cell and B cell immunity can be
reconstituted with mismatched hematopoietic stem cell trans-
plantation without alkylator therapy in artemis-deﬁcient mice using
anti-natural killer cell antibody and photochemically treated sensi-
tized donor T cells. Biol Blood Marrow Transplant. 2012;18:200-209.
82. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural
killer cell alloreactivity in mismatched hematopoietic transplants.
Science. 2002;295:2097-2100.
83. Handgretinger R. Negative depletion of CD3þ and TCRabþ T cells. Curr
Opin Hematol. 2012;19:434-439.
84. Xie M, Fu HX, Chang Y-J, et al. Characteristics and inﬂuencing factors
of CD19þ B cell reconstitution in patients following haploidentical/
Y.-J. Chang et al. / Biol Blood Marrow Transplant 20 (2014) 440e449 449mismatched hematopoietic stem cell transplantation. Int J Hematol.
2012;96:109-121.
85. Huang X-J, Xu L-P, Liu K-Y, et al. Partially matched related donor
transplantation can achieve outcomes comparable with unrelated
donor transplantation for patients with hematologic malignancies.
Clin Cancer Res. 2009;15:4777-4783.
86. Huang X-J, Liu DH, Liu K-Y, et al. Treatment of acute leukemia with
unmanipulated HLA-mismatched/haploidentical blood and bone
marrow transplantation. Biol Blood Marrow Transplant. 2009;15:
257-265.
87. Lu DP, Dong L, Wu T, et al. Conditioning including antithymocyte
globulin followed by unmanipulated HLA-mismatched/haploidentical
blood and marrow transplantation can achieve comparable outcomes
with HLA-identical sibling transplantation. Blood. 2006;107:
3065-3073.
88. Raiola AM, Dominietto A, Ghiso A, et al. Unmanipulated hap-
loidentical bone marrow transplantation and posttransplantation
cyclophosphamide for hematologic malignancies after myeloablative
conditioning. Biol Blood Marrow Transplant. 2013;19:117-122.
89. Marin IGG, Perez-Corral AM, Gayoso J, et al. Natural killer (NK) cell
reconstitution after haploidentical unmanipulated bone marrow
transplantation with reduced-intensity conditioning. ASH Annual
Meeting Abstracts. Blood. 2011;118:4557.
90. Koehl U, Bochennek K, Zimmermann SY, et al. Immune recovery in
children undergoing allogeneic stem cell transplantation: absolute
CD8þ CD3þ count reconstitution is associated with survival. Bone
Marrow Transplant. 2007;39:269-278.
91. Noviello M, Forcina A, Stanghellini MTL, et al. Early reconstitution of
T-cell immunity to CMV after HLA-haploidentical hematopoietic stem
cell transplantation is a strong surrogate biomarker for lower non-
relapse mortality rates. ASH Annual Meeting Abstracts. Blood. 2012;
120:4191.
92. Chang Y-J, Huang X-J. Haploidentical hematopoietic stem cell trans-
plantation with unmanipulated granulocyte colony-stimulating fac-
toremobilized marrow and blood grafts. Curr Opin Hematol. 2012;19:
454-461.
93. Dominietto A, Raiola AM, Bruno B, et al. Rapid immune reconstitution
following unmanipulated haploidentical BMT with post-transplant
high-dose cyclophosphamide ASH Annual Meeting Abstracts. Blood.
2011;118:3050.
94. Merindol N, Champagne MA, Duval M, Soudeyns H. CD8(þ) T-cell
reconstitution in recipients of umbilical cord blood transplantation
and characteristics associated with leukemic relapse. Blood. 2011;118:
4480-4488.
95. McIver ZA, Melenhorst JJ, Grim A, et al. Immune reconstitution in
recipients of photodepleted HLA-identical sibling donor stem cell
transplantations: T cell subset frequencies predict outcome. Biol Blood
Marrow Transplant. 2011;17:1846-1854.96. Gratama JW, Boeckh M, Nakamura R, et al. Immune monitoring with
iTAg MHC tetramers for prediction of recurrent or persistent cyto-
megalovirus infection or disease in allogeneic hematopoietic stem cell
transplant recipients: a prospective multicenter study. Blood. 2010;
116:1655-1662.
97. Wang Y, Liu DH, Xu LP, et al. Superior graft-versus-leukemia effect
associated with transplantation of haploidentical compared with
HLA-identical sibling donor grafts for high-risk acute leukemia: an
historic comparison. Biol Blood Marrow Transplant. 2011;17:821-830.
98. Yan CH, Liu DH, Liu KY, et al. Risk stratiﬁcationedirected donor
lymphocyte infusion could reduce relapse of standard-risk acute
leukemia patients after allogeneic hematopoietic stem cell trans-
plantation. Blood. 2012;119:3256-3262.
99. Zhao XS, Jin S, Zhu HH, et al. Wilms’ tumor gene 1 expression: an
independent acute leukemia prognostic indicator following allogeneic
hematopoietic SCT. Bone Marrow Transplant. 2012;47:499-507.
100. Zhao XS, Liu YR, Zhu HH, et al. Monitoring MRD with ﬂow cytometry:
an effective method to predict relapse for ALL patients after allogeneic
hematopoietic stem cell transplantation. Ann Hematol. 2012;91:
183-192.
101. Szabolcs P, Niedzwiecki D. Immune reconstitution after unrelated
cord blood transplantation. Cytotherapy. 2007;9:111-122.
102. Brown JA, Stevenson K, Kim HT, et al. Clearance of CMV viremia and
survival after double umbilical cord blood transplantation in adults de-
pends on reconstitution of thymopoiesis. Blood. 2010;115:4111-4119.
103. Sauter C, Abboud M, Jia X, et al. Serious infection risk and immune
recovery after double-unit cord blood transplantation without
antithymocyte globulin. Biol Blood Marrow Transplant. 2011;17:
1460-1471.
104. June CH, Blazar BR, Riley JL. Engineering lymphocyte subsets: tools,
trials and tribulations. Nat Rev Immunol. 2009;9:704-716.
105. Oliveira G, Greco R, Lupo-Stanghellini MT, et al. Use of TK-cells in
haploidentical hematopoietic stem cell transplantation. Curr Opin
Hematol. 2012;19:427-433.
106. Li HW, Sykes M. Emerging concepts in haematopoietic cell trans-
plantation. Nat Rev Immunol. 2012;12:403-416.
107. Zhang J, Barefoot BE, Mo W, et al. CD62L- memory T cells enhance T-
cell regeneration after allogeneic stem cell transplantation by elimi-
nating host resistance in mice. Blood. 2012;119:6344-6353.
108. Stern M, Passweg JR, Meyer-Monard S, et al. Pre-emptive immuno-
therapy with puriﬁed natural killer cells after haploidentical SCT: a
prospective phase II study in two centers. Bone Marrow Transplant.
2013;48:433-438.
109. Chou JF, Kernan NA, Prockop S, et al. Safety and immunogenicity
of the live attenuated varicella vaccine following T cellereplete or T
cell-depleted related and unrelated allogeneic hematopoietic cell
transplantation (alloHCT). Biol Blood Marrow Transplant. 2011;17:
1708-1713.
